CATALOGO DEI PRODOTTI DELLA RICERCA

LANZAFAME, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.785
NA - Nord America 2.564
AS - Asia 1.760
SA - Sud America 268
AF - Africa 43
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.428
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.502
RU - Federazione Russa 1.150
SG - Singapore 772
CN - Cina 570
GB - Regno Unito 518
BR - Brasile 231
SE - Svezia 194
IT - Italia 170
DE - Germania 167
IE - Irlanda 156
FR - Francia 144
HK - Hong Kong 144
FI - Finlandia 131
VN - Vietnam 110
KR - Corea 38
UA - Ucraina 36
CA - Canada 35
JP - Giappone 26
ZA - Sudafrica 23
IN - India 21
AR - Argentina 20
CZ - Repubblica Ceca 20
PL - Polonia 20
MX - Messico 18
NL - Olanda 16
TR - Turchia 16
ID - Indonesia 15
BE - Belgio 13
BD - Bangladesh 11
AT - Austria 8
BF - Burkina Faso 8
ES - Italia 8
CO - Colombia 7
IQ - Iraq 7
LT - Lituania 7
UZ - Uzbekistan 5
PK - Pakistan 4
RO - Romania 4
AU - Australia 3
CH - Svizzera 3
CL - Cile 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HU - Ungheria 3
IL - Israele 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
EC - Ecuador 2
EE - Estonia 2
EG - Egitto 2
EU - Europa 2
HR - Croazia 2
KH - Cambogia 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BJ - Benin 1
CD - Congo 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
MN - Mongolia 1
NO - Norvegia 1
PS - Palestinian Territory 1
PY - Paraguay 1
RS - Serbia 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UG - Uganda 1
VE - Venezuela 1
Totale 7.428
Salva come PNG Salva come JPEG
Città #
Singapore 417
Southend 416
Moscow 409
Chandler 389
Jacksonville 244
Woodbridge 234
Ashburn 206
Dallas 190
Dublin 155
Hong Kong 144
Ann Arbor 140
Beijing 120
New York 63
Los Angeles 61
Lawrence 53
Princeton 53
Helsinki 48
Houston 45
Jinan 45
Munich 45
Nanjing 44
Shenyang 43
Wilmington 43
Ho Chi Minh City 38
Verona 36
The Dalles 33
Tokyo 24
Santa Clara 23
Hebei 21
São Paulo 20
Turku 20
Warsaw 20
Denver 19
Hanoi 19
Brno 18
Buffalo 18
London 18
Tianjin 18
Boardman 16
Bologna 16
Council Bluffs 16
Redondo Beach 16
Seoul 16
Atlanta 15
Ningbo 15
Haikou 14
Johannesburg 14
Toronto 14
Zhengzhou 14
Bloomsbury 13
Brussels 13
Montreal 13
Sindelfingen 13
Changsha 12
Frankfurt am Main 11
Guangzhou 11
Hangzhou 11
Nanchang 11
Orem 11
San Francisco 11
Taizhou 11
Boston 10
Columbus 10
Jiaxing 10
Milan 10
Redmond 10
Seattle 10
Chennai 9
Norwalk 9
Phoenix 9
Redwood City 9
Stockholm 9
Brooklyn 8
Dong Ket 8
Fuzhou 8
Jakarta 8
Ouagadougou 8
Rio de Janeiro 8
Clearwater 7
Lanzhou 7
Manchester 7
Nuremberg 7
Poplar 7
Amsterdam 6
Belo Horizonte 6
Chicago 6
Falls Church 6
Taiyuan 6
Washington 6
Curitiba 5
Da Nang 5
Haiphong 5
Pignone 5
Querétaro 5
San Jose 5
Tashkent 5
Ankara 4
Bogotá 4
Bursa 4
Fairfield 4
Totale 4.534
Salva come PNG Salva come JPEG
Nome #
Performance of alere determine HIV-1/2 Ag/Ab combo rapid test for acute HIV infection: A case report | Performance del test rapido Alere Determine HIV-1/2 Ag/Ab Combo nell?infezione acuta da HIV: Un caso clinic 221
Cryptococcal dermatitis with negative antigenaemia heralding disseminated disease in HIV infection. 202
Benign acute viral myositis in African migrants: a clinical, serological and pathological study. 188
A 58-year-old man with B-cell chronic lymphocytic leukemia and multiple strokes 183
Disseminated Mycobacterium chimaera infection after open heart surgery in an Italian woman: a case report and a review of the literature 182
Acute mediastinitis: a severe complication of transdermal therapy in a patient with ischaemic heart disease. A case report. 181
HIV-1-associated neurocognitive disorders: is HLA-C binding stability to β2-microglobulin a missing piece of the pathogenetic puzzle? 181
Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load 168
Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up 166
Successful Antifungal Combination Therapy and Surgical Approach for Aspergillus fumigatus Suppurative Thyroiditis Associated with Thyrotoxicosis and Review of Published Reports 166
Pneumatocoele formation during Pneumocystis carinii pneumonia in a man with HIV-1 infection. 165
'High' antiretroviral deintensification strategy and cellular HIV DNA levels 165
Primary cutaneous cryptococcosis in a HIV infested patient: case report. 158
Is there a role for TNF-alpha in HIV1-associated lipodystrophy? 157
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient 156
Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life 156
Histoplasmosis in two human immunodeficiency virus-positive immigrants to Italy: clinical features and management in the highly active antiretroviral therapy era. 154
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients 154
No improvement of lipodystrophy syndrome in an HIV-infected patient. 152
Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients 148
Recreational substance use and tolerance of efavirenz in HIV-1 infected patients 147
Monoclonal gammopathy in HIV-Infected patients on stable antiretroviral therapy: disappearance or deep reduction? 145
Can we really identify HIV-1 long-term nonprogressors? 143
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir 143
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study 143
Short-Cycle Therapy (5 days on/2 days off) with a lamivudine-dolutegravir two-drug regimen in a cohort of virologically suppressed HIV-infected patients 142
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy: clinical implications in patients on CD4 T-cell-guided treatment interruption. 141
Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients 141
Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report. 139
Unusual rapidly growing ulcerative genital mass due to herpes simplex virus in uman immunodeficiency virus-infected woman 133
Antiretroviral therapy in low-resource settings 132
Efficacy and safety of TAM-sparing antiretroviral regimens in naive HIV-positive patients 129
Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report 126
Prevalence of Strongyloides stercoralis infection among HIV-positive immigrants attending two Italian hospitals, from 2000 to 2009. 122
Relationship between vertebral fractures, bone mineral density, and osteometabolic profile in HIV and Hepatitis B and C-infected patients treated with ART 122
Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials 121
Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients 121
Efavirenz dose reduction in HIV-infected patients: a long-term follow-up 118
Disappearance of Renal Stones in an HIV-1-Infected Patient After Reduction of Atazanavir Dose 117
Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection 114
Raltegravir: is a 400 mg once-daily dose enough? 114
Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor 113
Inflammatory pseudotumor of lymph nodes. 110
Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up 109
The treatment of latent TB infection in HIV-positive people: the Verona experience 108
Quantitative Trait Loci for CD4:CD8 Lymphocyte Ratio Are Associated with Risk of Type 1 Diabetes and HIV-1 Immune Control 107
Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings 106
The major genetic determinants of HIV-1 control affect HLA Class I Peptide presentation 104
Prevalence and clinical significance of Ureaplasma urealyticum and Mycoplasma hominis in the lower genital tract of HIV-1-infected women. 102
No influence of nevirapine on vitamin D deficiency in HIV-infected patients 98
Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital 95
Short-cycle therapy in {HIV}-infected adults: rilpivirine combination 4 days on/3 days off therapy 86
Prior Mycobacterium avium complex infection is linked to immunological nonresponsiveness in HIV-infected patients on highly active antiretroviral therapy 72
Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose. 70
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study 56
WISE (Web-based Infectious Support for the Elderly) Initiative: Improving Infectious Disease Management in LTCFs-Experience From Northern Italy 24
Totale 7.516
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.267
article - articoli 25.267
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.534
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021199 0 0 0 0 0 47 11 32 21 19 46 23
2021/2022489 44 151 4 66 6 8 5 22 26 15 32 110
2022/20231.035 58 137 83 164 100 256 3 71 122 6 20 15
2023/2024486 26 45 52 39 63 84 6 26 6 28 63 48
2024/20251.148 59 81 37 175 59 27 66 39 184 71 105 245
2025/20262.564 256 200 188 637 1.038 245 0 0 0 0 0 0
Totale 7.516